ENDRA Life Sciences Return on Equity

ENDRA Life Sciences (NDRA) currently reports a ROE of -93.77%. That is below the Technology sector average of 47.96%. Use the charts on this page to explore ENDRA Life Sciences's ROE history and peer comparisons.

ENDRA Life Sciences's ROE of -93.77% is lower than the Technology sector average of 47.96%. That is roughly 295.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ENDRA Life Sciences's current -93.77% should be judged against Technology norms (sector average: 47.96%) and against NDRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -93.77%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 47.96%. From there, open related valuation or income-statement pages for ENDRA Life Sciences, and consider following NDRA for alerts when major investors trade the stock.

ENDRA Life Sciences is classified in the Technology sector. On ROE, it currently shows -93.77% versus a sector average near 47.96%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing NDRA with unrelated industries.